The DOJ's decision to reschedule marijuana is the biggest federal cannabis policy change in decades. Moments like this have historically sparked significant moves in the stocks directly affected.
The removal of the IRC Section 280E tax rule means cannabis companies can now claim standard business deductions — something that was previously denied to them. That change alone could transform the profitability of companies in this group.
From pharmaceutical researchers to institutional investors, this reclassification has put cannabis firmly on the radar of serious market participants. Professional analysts curated this basket to capture the companies best positioned to benefit.
Total market cap is $.000 and the basket currently has no constituents, so it lacks large-cap anchors. Consequently, there is no inherent market-cap profile to assess.
The U.S. Department of Justice's decision to move marijuana from Schedule I to Schedule III is one of the most significant regulatory shifts in cannabis history. This change bridges the gap between federal prohibition and state-level medical programmes, and our analysts believe it unlocks a wave of new profitability for companies across the cannabis value chain — from cultivators to pharmaceutical researchers.
This is a high-growth, catalyst-driven theme, meaning it's built around a specific policy event rather than long-term earnings history. The removal of the IRC Section 280E tax burden — which previously prevented cannabis businesses from claiming standard deductions — could dramatically improve cash flows. This group includes individual stocks and ETFs, offering both targeted and diversified exposure.
Every asset in this group was handpicked by professional analysts as a direct or indirect beneficiary of the DOJ rescheduling decision. Whether it's licensed medical producers gaining operational advantages, pharmaceutical researchers facing fewer regulatory hurdles, or sector-tracking ETFs capturing broad market optimism, each pick has a clear and reasoned connection to this historic policy shift.
The DOJ's historic move to reclassify marijuana as a Schedule III drug is removing massive tax burdens and sparking immediate optimism across the cannabis sector. This policy shift unlocks new profitability and operational pathways for medical producers, dispensaries, and pharmaceutical researchers navigating the newly regulated landscape.
이 바스켓의 전체 스토리를 확인하세요. 리스크와 잠재력을 다룬 상세 기사를 읽어보세요.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
4월 24 게시
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+1
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
이 자산들에 투자했다면:
12개월 후 예상 가치:
+263.21%
애널리스트들은 이 그룹의 자산이 향후 1년간 평균 263.21% 성장할 것으로 예상합니다.
이 그룹의 자산 10개 중 1개가 전문 애널리스트로부터 매수 의견을 받았습니다.
